AcuCort (ACUC) Q1 2026 earnings summary

Executive summary

• No revenue generated in Q1 2026; net loss after tax was -6,833 KSEK compared to -6,522 KSEK in Q1 2025.

• Cash position at period end was 21,153 KSEK.

• Signed a commercial agreement with Glenmark Pharmaceuticals for six European countries.

• Reached agreement with FDA on iPSP, removing a key regulatory hurdle for US market entry.

Financial highlights

• Net loss after tax for Q1 2026 was -6,833 KSEK, slightly higher than -6,522 KSEK in Q1 2025.

• Earnings per share before and after dilution was -0.03 SEK, unchanged from Q1 2025.

• Cash and cash equivalents at quarter end were 21,153 KSEK, down from 27,012 KSEK at year-end 2025.

• Total assets at March 31, 2026, were 62,208 KSEK.

• 2,150 KSEK in development expenses were capitalized as intangible assets.

Outlook and guidance

• Expects increased sales as Zeqmelit® becomes more established in the Nordic market.

• Anticipates further regulatory approvals outside the Nordics, with Glenmark planning launches in six European countries in 2027.

• Plans to submit a US market application for Zeqmelit® in 2026.

• Working to expand into additional European countries and the US, aiming for further revenue growth.